News

NeuroAiD at World Congress of Neurology

By | News

Moleac’s flagship product, NeuroAiD, will be presented at the 23rd Word Congress of Neurology during oral abstract presentations by A/Prof. Alice Theadom from New-Zealand.

    • A Randomized, Placebo-controlled Pilot Trial to Investigate the Safety and Efficacy of MLC901 (NeuroAiDIITM) in Adults Following Mild or Moderate Traumatic Brain Injury – 19th September, 11:40 – 11:50.

In addition, Moleac will be hosting a symposium on the 17th September with renowned researchers in the field of neurology, to cover the following topics:

    • Prof. Jose Navarro from the Philippines, one of the principal investigators of NeuroAiD’s landmark studies, CHIMES and CHIMES-E, will present NeuroAiD’s long-term benefits in post-stroke recovery and the latest analyses conducted on prognostic factors or poorer outcomes.
    • Prof. Marasigan from the Philippines, will introduce NEURITES, ongoing clinical trial on NeuroAiD in vascular cognitive impairments.

NeuroAiD (either MLC 601 or MLC 901), as first known as a Traditional Chinese Medicine, is a natural product combining several active ingredients including nine herbal extracts in the form of capsules. It is a claimed treatment for stroke sold by Moleac Pte Ltd, a biopharmaceutical company in Singapore. Since its first commercialization in 2006, NeuroAiD™ has shown a rapid and stable growth internationally, and is available today in numerous countries of several regions (South East Asia, Europe, Middle East, and Africa). Pharmacology research has established the neuroprotective and neurorestorative activities of NeuroAiD providing possible mechanisms for neurological recovery in post-stroke survivors. 

Moleac is a pharmaceutical company headquartered in Singapore and focused on developing and commercializing treatment for the patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Moleac was founded by French entrepreneurs and scientists in 2002 and is headquartered in Singapore.

NeuroAiD presentations at European Stroke Conference

By | News

NeuroAiD, Moleac’s main product, will be presented at the 26th European Stroke Conference on 24th May during abstract presentations on the 24th and 26th May by A/Prof. Narayanaswamy Venketasubrmanian:

  • Comparison of Long-term Spontaneous Functional Recovery and Response to Treatment with MLC601 between Cortical and Non-cortical strokes – The CHIMES-E study (24th May)
  • Targeting Stroke Patients with a Higher Potential of Long-term Benefit from Treatment: Insights from the CHIMES-E Study (26th May)
  • Synergistic Effect of Combining MLC601 and Rehabilitation on Post-stroke Recovery – The CHIMES Study (26th May)

In addition, Moleac will be hosting an evening symposium on the 25th May with recognised leaders in the field of stroke and pre-clinical research, to cover the following topics:

  • Prof. Tatjana Rundek from the Unites States will present her work on long-term prognosis and outcome of patients after stroke.
  • Prof. Michel Lazdunski from France, who has conducted several important preclinical studies on NeuroAiD with his team, will present neurorestorative strategies from natural substances.
  • Prof. N Venketasubramanian (Ramani) from Singapore, one of the principal investigators of NeuroAiD’s landmark studies, will present CHIMES and CHIMES-E key outcomes NeuroAiD clinical benefit on post-stroke recovery and insights regarding patients’ selection for clinical research.

NeuroAiD (either MLC 601 or MLC 901), as first known as a Traditional Chinese Medicine, is a natural product combining several active ingredients including nine herbal extracts in the form of capsules. It is a claimed treatment for stroke sold by Moleac Pte Ltd, a biopharmaceutical company in Singapore. Since its first commercialization in 2006, NeuroAiD™ has shown a rapid and stable growth internationally, and is available today in numerous countries of several regions (South East Asia, Europe, Middle East, and Africa). Pharmacology research has established the neuroprotective and neurorestorative activities of NeuroAiD providing possible mechanisms for neurological recovery in post-stroke survivors.

Moleac is a pharmaceutical company headquartered in Singapore and focused on developing and commercializing treatment for the patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Moleac was founded by French entrepreneurs and scientists in 2002 and is headquartered in Singapore.

NeuroAiD presentations at European Stroke Organisation Conference

By | News

NeuroAiD, Moleac’s main product, will be presented at the 3rd European Stroke Organisation Conference on 16th May during the following poster presentations:

  • Synergistic Effect of Combining MLC601 and Rehabilitation on Post-stroke Recovery – The CHIMES Study
  • Targeting Stroke Patients with a Higher Potential of Long-term Benefit from Treatment: Insights from the CHIMES-E Study

NeuroAid data will also be presented during an abstract presentation on the 18th May by Prof. Christopher Chen, National University of Singapore:

  • Comparison of Long-term Spontaneous Functional Recovery and Response to Treatment with MLC601 between Cortical and Non-cortical strokes – The CHIMES-E study

In addition, Moleac will be hosting an evening symposium on the 16th May with world-class leaders in stroke research, to cover the following topics:

  • Prof. Pamela Duncan from the United States will present her extensive research on capturing outcomes after stroke.
  • Prof. Christopher Chen from Singapore, one of the principal investigators of NeuroAiD’s landmark studies CHIMES and CHIMES-E studies, will present the long term benefits of NeuroAiD on post-stroke recovery.
  • Dr. Boutarene and Dr. Bouabdallah from Algeria will present the observational study they conducted on NeuroAiD with NeST Registry.

NeuroAiD (either MLC 601 or MLC 901), as first known as a Traditional Chinese Medicine, is a natural product combining several active ingredients including nine herbal extracts in the form of capsules. It is a claimed treatment for stroke sold by Moleac Pte Ltd, a biopharmaceutical company in Singapore. Since its first commercialization in 2006, NeuroAiD™ has shown a rapid and stable growth internationally, and is available today in numerous countries of several regions (South East Asia, Europe, Middle East, and Africa). Pharmacology research has established the neuroprotective and neurorestorative activities of NeuroAiD providing possible mechanisms for neurological recovery in post-stroke survivors.

Moleac is a pharmaceutical company headquartered in Singapore and focused on developing and commercializing treatment for the patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Moleac was founded by French entrepreneurs and scientists in 2002 and is headquartered in Singapore. 

Launch of NeuroAiD in Nigeria

By | News

Helping patients reconnect with their lives remain our focus. This February, NeuroAiD will be launched in Nigeria in association with our local distributor, Bolar Pharmaceuticals. Nigeria is one of the most populous nations in Africa, and has recently faced an increasing prevalence of stroke (>250,000 in 2015*) and other cardiovascular diseases. NeuroAiD is bringing a unique evidence-based therapeutic opportunity for the victims to recover faster and better.

*Global Burden Disease 2015 data

Moleac awarded prize from Creative France – recognising the success of French entrepreneurs in Singapore

By | News

“Entrepreneur” is a French invention for risk takers committed to innovate, and Moleac is a complete illustration of successful entrepreneurial biopharmaceutical company in Singapore.

A quote from his Excellency, Ambassador Benjamin Dubertret, French Ambassador in Singapore
“The “Creative Next” contest aims at showcasing French ingenuity and identifying inspirational French entrepreneurs or SMEs that have demonstrated creativity and innovation in their business. Thanks to its innovative therapeutic solutions to neurological diseases, finalist company Moleac perfectly embodies the essence of French “creativité”: an exceptional ability to innovate paired with scientific excellence and talent.”

In 2016, Moleac celebrated the 10 years’ anniversary of its flagship product, NeuroAiD.

NeuroAiD was initially launched in Singapore in 2006 and rapidly expended to over 35 countries worldwide. This innovative product fulfills a major therapeutic gap for stroke victims in their journey to recover their functional independence. Today, NeuroAiD is in the running to become Singapore’s first home-grown drug.

The idea was born in France and initially funded from Europe. We saw the opportunity to bridge the gap between Traditional Chinese Medicine (TCM) and Western medicine, two paths which usually don’t cross at all. The decision to locate the company in Singapore was based on the understanding of both Eastern and Western medicine here in Singapore, which is essential for NeuroAiD’s development. We also wanted to ensure our research and data could stand the scrutiny of clinicians internationally. In the past 10 years, NeuroAiD has undergone clinical trials in Singapore and internationally, demonstrating its efficacy in boosting recovery of neurological functions after a stroke. NeuroAiD has reached 20,000 patients last year and we are currently working towards obtaining full-fledged drug approval in the United States and Europe.

We are honored to receive this award from Creative France which represents wider recognition of our commitment to innovate and bring therapeutic solutions to thousands of stroke victims worldwide.

NeuroAiD (either MLC 601 or MLC 901), as first known as a Traditional Chinese Medicine, is a natural product combining several active ingredients including nine herbal extracts in the form of capsules. It is a claimed treatment for stroke sold by Moleac Pte Ltd, a biopharmaceutical company in Singapore. Since its first commercialization in 2006, NeuroAiD™ has shown a rapid and stable growth internationally, and is available today in numerous countries of several regions (South East Asia, Europe, Middle East, and Africa). Pharmacology research has established the neuroprotective and neurorestorative activities of NeuroAiD providing possible mechanisms for neurological recovery in post-stroke survivors.

Moleac is a pharmaceutical company headquartered in Singapore and focused on developing and commercializing treatment for the patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Moleac was founded by French entrepreneurs and scientists in 2002 and is headquartered in Singapore.

Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD™) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study

By | News

Cerebrovasc Dis 2017; 43:36-42

Published by S. Karger AG, Basel

This analysis from the CHIMES-E study shows that subjects with prognostic factors of poorer outcome get a higher benefit on post-stroke functional recovery with a 3-month course of NeuroAiD compared to placebo, with statistically significant differences seen as early as 3 months and persisting over the long term. At 12 months NeuroAiD almost doubles the chances of achieving functional independence. These results indicate that selection of subjects with poorer prognosis, particularly those with more severe NIHSS score and longer OTT* delay, as well as a longer follow-up period and treatment duration can maximize the recovery potential of subjects included in post-acute stroke clinical trials.

Authors: Narayanaswamy Venketasubramanian, Chun Fan Lee, Sherry H. Young, San San Tay, Thirugnanam Umapathi, Annabelle Y. Lao, Herminigildo H. Gan, Alejandro C. Baroque II, Jose C. Navarro, Hui Meng Chang, Joel M. Advincula, Sombat Muengtaweepongsa, Bernard P.L. Chan, Carlos L. Chua, Nirmala Wijekoon, H. Asita de Silva, John Harold B. Hiyadan, Nijasri C. Suwanwela, K.S. Lawrence Wong, Niphon Poungvarin, Gaik Bee Eow, Christopher L.H. Chen for the CHIMES-E Study Investigators

Keywords: Acute stroke, Stroke recovery, MLC601, NeuroAiD, Prognosis, Clinical trial, Long-term outcome

Abstract:

Background: The Chinese Medicine NeuroAiD Efficacy on Stroke recovery – Extension (CHIMES-E) study is among the few acute stroke trials with long-term outcome data. We aimed to evaluate the recovery pattern and the influence of prognostic factors on treatment effect of MLC601 over 2 years.

Methods: The CHIMES-E study evaluated the 2 years outcome of subjects aged ≥ 18 years with acute ischemic stroke, National Institutes of Health Stroke Scale (NIHSS) score 6–14, pre-stroke modified Rankin Scale (mRS) score ≤ 1 included in a multicenter, randomized, double-blind, placebo-controlled trial of MLC601 for 3 months. Standard stroke care and rehabilitation were allowed during follow-up with mRS score being assessed in-person at month (M) 3 and by telephone at M1, M6, M12, M18 and M24.

Results: Data from 880 subjects were analyzed. There was no difference in baseline characteristics between treatment groups. The proportion of subjects with mRS score 0–1 increased over time in favor of MLC601 most notably from M3 to M6, thereafter remaining stable up to M24, while the proportion deteriorating to mRS score ≥ 2 remained low at all time points. Older age (p < 0.01), female sex (p = 0.06), higher baseline NIHSS score (p < 0.01) and longer onset to treatment time (OTT; p< 0.01) were found to be predictors of poorer outcome at M3. Greater treatment effect, with more subjects improving on MLC601 than placebo, was seen among subjects with 2 or more prognostic factors (OR 1.65 at M3, 1.78 at M6, 1.90 at M12, 1.65 at M18, 1.39 at M24), especially in subjects with more severe stroke or longer OTT.

Conclusions: The sustained benefits of MLC601 over 2 years were due to more subjects improving to functional independence at M6 and beyond compared to placebo. Selection of subjects with poorer prognosis, particularly those with more severe NIHSS score and longer OTT delay, as well as a long follow-up period, may improve the power of future trials investigating the treatment effect of neuroprotective or neurorestorative therapies.

 

Download the full paper

Moleac’s Flagship Product NeuroAiD Named Asia Pacific Neurological Disorders New Product Innovation of the Year At the Frost & Sullivan Best Practices Awards

By | News

NeuroAiDTM has been named New Product Innovation of the Year by Frost & Sullivan. This award recognizes healthcare products that are bringing innovative solutions for neurological disorders by pushing the boundaries of the usual practices. This award also acknowledges Moleac for its effort and continuous investment in NeuroAiDTM‘s Research and Development. Mr. David Picard, CEO of Moleac, received the 2016 Frost & Sullivan Asia Pacific New Product Innovation Award at the awards ceremony held this evening at Conrad Singapore. The ceremony was attended by leaders from the healthcare sector.

Frost & Sullivan followed a rigorous measurement-based methodology to select NeuroAiDTM as the recipient. Its independent panel of judges included senior members across various offices at Frost & Sullivan. The judging panel looked at market performance indicators, including revenue growth, market share, availabilities, geographical expansion and marketing strategies. The full  Frost & Sullivan Award Research Report for Moleac is available here.

Dr. M. Shaillender, Industry Analyst, Healthcare Practice – Asia Pacific at Frost & Sullivan, said, “Stroke rehabilitation is an underserved segment in the pharmaceutical industry. Moleac aims to address the existing gaps in stroke therapy with an unconventional approach similar to reverse innovation.’ NeuroAiDTM is a product originating from Traditional Chinese Medicine that has demonstrated excellent attributes in post-stroke recovery, however, without any scientific and clinical evidence. Moleac’s team was instrumental in identifying and decoding the underlying neuromodulatory properties to translate it into a therapeutic drug supported by clinical evidence for neurological disorders.”

He further adds, “As one of the first therapies of its kind, NeuroAiDTM is today accepted as an innovative treatment for post-stroke recovery. It is approved and marketed in over 35 countries as a supplement for stroke rehabilitation. Executing well in its vision, Moleac is on a trajectory to expand the horizons of NeuroAiDTM into a mainstream therapeutic drug for neurological disorders.”

David Picard, CEO of Moleac, said, “I am delighted to receive this award from Frost & Sullivan while we are celebrating the 10 years’ anniversary of NeuroAiDTM. Having launched NeuroAiDTM in 2006, we have been focusing our efforts on making NeuroAiDTM available to stroke sufferers around the world. NeuroAiDTM is the first medicine to support stroke recovery, and this is a huge unserved need for millions of suffers. In 2016, over 20,000 patients benefited from NeuroAiDTM worldwide and we aim at making NeuroAiDTM available to more patients in the coming years.”

He continued to add, “I would like to thank all those who have contributed to NeuroAiDTM‘s development over the past 10 years. This includes our academic partners, who have shown interest in our approach enabling its clinical development, our investors who have trusted us, and of course my colleagues who have made this venture a success. Without their support, NeuroAiDTM would not be where it is today. We keep investing in Research with several on-going clinical studies to provide first-class evidences of NeuroAiDTM‘s benefits in other unserved neurological disorders.”

NeuroAiDTM is a natural medicine originating from Traditional Chinese Medicine. In addition to its excellent safety profile, clinical trials have shown that patients taking NeuroAiDTM for 3 months have higher chances to reach functional recovery, with prolonged benefits over the long-term as published in Cerebrovascular Diseases (April 2015). About 3,000 subjects have been included in clinical trials and Moleac is currently supporting additional international clinical trials to demonstrate the potential of NeuroAiDTM in other neurological disorders.

About Moleac: Moleac is a Singapore-based biopharmaceutical company that dedicates itself to finding and developing new medicines for the unmet needs of patients worldwide.

About NeuroAiDTM: NeuroAiDTM is a post-stroke recovery treatment to help stroke survivors achieve a faster and better recovery. Moleac also markets NeuroAiD II, a simplified formula. Both products are shown to be equivalent in pharmacology. It currently reaches out to patients in over 35 countries.

chimes society

NeuroAiD™ has shown persistent long-term benefits after an initial 3-month treatment following stroke onset

By | News

Moleac is pleased to announce the release of the CHIMES-E study results published online in the journal Cerebrovascular Diseases1 . It provides convincing data on NeuroAiD which confirm its persistent long-term benefits on patients’ recovery after an ischemic stroke. The CHIMES-E study results were first announced by Prof. Christopher Chen (CHIMES-E co-principal investigator) during the European Stroke Organization Conference (ESOC 2015) in Glasgow, April 17- 19, as part of the Scientific Program during the Clinical Trial session.

The CHIMES-E study is a planned, international and multicenter study performed in a blinded and placebo-controlled manner. It has included 880 patients from the CHIMES study who have suffered an ischemic stroke of intermediate severity within 72 hours, treated with NeuroAiD™ or placebo for 3 months after the initial stroke. The main purpose of this study was to evaluate the effects of an initial 3-month course with NeuroAiD™ on long-term outcomes for up to 2 years.

This study has showed that NeuroAiD™ increases significantly the odds of achieving functional independence at 6 months which persisted up to 18 months after stroke, as measured by the mRS. All these results were consistent at various time points and seen on 2 indices, i.e. mRS and BI. It also provided further long-term safety data on NeuroAiD™, even when combined with other stroke treatments. “These persistent benefits seen up to 18 months are a clinical confirmation of the previously established neurorestorative properties (i.e. neuroplasticity and neurogenesis) of NeuroAiD™, and suggest that it may be beneficial to extend NeuroAiD™ treatment beyond the first 3 months after stroke,” said Prof. Christopher Chen, neurologist at the National University of Singapore and the principal investigator of the CHIMES study. “The CHIMES-E study provides new insight on the need for long-term assessment of post-stroke recovery in clinical trials of agents with neuroprotective and neurestorative properties such as NeuroAiD.

These results confirm the hypothesis raised by the CHIMES investigators: longer treatment duration and follow-up beyond 3 months of stroke patients is needed to assess stroke recovery2

About CHIMES Society

The CHIMES Society is an international academic industry collaboration with the objective to establish new stroke treatments. It is a Singaporean non-profit society founded by a group of experts in stroke and South-East Asian stroke clinicians interested to implement a research project: the NeuroAiD™ Efficacy on stroke recovery trial (CHIMES trial).

The CHIMES-E Study was supported by the CHIMES society and grants were received by CHLC from the National Medical Research Council in Singapore (NMRC) which supports the implementation of CHIMES trial in Singapore.

About Moleac

To address therapeutic gaps, Moleac has pioneered a new drug development approach, looking at sources of innovation from Natural Medicines, hence shortening considerably drug development cycle time and investment to bring medicine to sufferers’ unaddressed needs. Moleac’s neurorestorative compound NeuroAiD™ reaches patients in more than 30 countries.

For more information,

contact: news@chimes-society.org

1- Venketasubramanian N, et al. CHInese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study (CHIMES-E): A Multicenter Study of Long-Term Efficacy. Cerebrovascular Diseases 2015;44 39:309–318.

2- Venketasubramanian N, et al. Chinese medicine NeuroAiD efficacy stroke recovery-extension study (CHIMES-E study): an observational multicenter study to investigate the longer-term efficacy of NeuroAiD in stroke recovery. Cerebrovasc Dis 2013; 35(suppl 1):18–22.

Archived News

By | News

Press Releases

2015

June 2015 Media article “Chinese Herbal Medicine May Have Delayed Benefit in Stroke”

A press article detailing the exciting new clinical results of CHIMES-E study showing the persisting benefits of NeuroAiD in post-stroke recovery was published online on Medscape.com

EN      
June 2015 Press Release “NeuroAiD™ has shown persistent long-term benefits after an initial 3-month treatment following stroke onset”

Moleac is pleased to announce the release of the CHIMES-E study results published online in the journal Cerebrovascular Diseases. It provides convincing data on NeuroAiD which confirm its persistent long-term benefits on patients recovery after an ischemic stroke. The CHIMES-E study results were first announced by Prof. Christopher Chen (CHIMES-E co-principal investigator) during the European Stroke Organization Conference (ESOC 2015) in Glasgow, April 1719, as part of the Scientific Program during the Clinical Trial session.

EN      
SP      

2014

August 2014 Presentation 27th August 2014 – Moleac’s CEO, David Picard, presented on “E-Commerce: Going beyond the traditional visibility of Pharma Products” at the Pharmaceutical Congress Asia that was held from 26th to 29th August 2014 at the Park Royal Hotel in Singapore. His presentation included an introduction to NeuroAiD™ as well as Moleac’s Corporate Social Responsibility (CSR) activities and commitment to patient care via the Stroke Recovery Coach. EN
July 2014 Press Article “TCM trial for stroke survivors – Professor Christopher Chen is interviewed about the NeuroAiD™II in Vascular Cognitive Impairment Study (NEURITES) in The Straits Times.” EN      
July 2014 Press Article “NUS studies the efficacy of traditional Chinese Medicine in treating stroke’s after-effects – featured in Lian He Zao Pao” CH      
April 2014 Press Release Moleac is happy to announce the appointment of Elmar Schnee as non-executive Chairman of the company EN      
Jan – Feb 2014 Press Article “Demonstrated efficiency of NeuroAiD™”

A press article detailing the exciting latest clinical data on vascular events reduction after a stroke has been published in the magazine “Actifs”

EN / FR      

2013

Oct 2013 Press Release NeuroAiD™, a treatment for post-stroke recovery, reduced early cardiovascular events and deaths by half after stroke

Singapore, 21st October 2013 – Early vascular events are an important cause of morbidity and mortality in the first three months after a stroke. The CHIMES Study is a placebo-controlled trial of NeuroAiD™, having included 1099 patients with ischemic stroke and receiving appropriate secondary prevention treatments. The frequency of early cardiovascular events and deaths during the 3-month follow-up was significantly halved in the NeuroAiD™, group (p=0.025) without an increase in bleeding rate and non-vascular deaths.

EN      
Jul 2013 Radio Interview Presenter of ‘Body & Soul’ program on 938LIVE Daniel Martin interviews Prof Christopher Chen on Stroke in Singapore and the CHIMES Study.

938LIVE is a poplar news-focused radio station. ‘Body & Soul’, since it first aired in 2007, has been Singapore’s only dedicated daily health radio talk-show.

EN      
Jun 2013 Press Release Stroke Treatment based on Traditional Chinese Medicine increases chances of recovery

  • CHIMES Society, a unique international partnership of experts in strokes undertakes first large-scale endeavour to investigate the use of a treatment derived from natural substances in stroke management.
  • Rigorous study shows ischemic stroke patients of intermediate severity who take NeuroAiD at acute stage had an 11 % increase in the odds of achieving independence and being able to perform daily activities at the end of three months.
  • Effect was even greater when NeuroAiD was started beyond 48 hours after stroke onset, with an increase of 39%.
EN      
Mar 2013 Press Release NeuroAiD™, a stroke treatment based on traditional Chinese medicine, more than doubles the chances of achieving independence after stroke

Singapore, March 19 2013: Authors of a medical paper published in this month’s Cerebrovascular Diseases journal found that NeuroAiD™ significantly improves patients’ independence after suffering a stroke compared to other control groups. During the studies stroke patients taking NeuroAiD™ were twice as likely able to take care of themselves and speak freely. The study also showed that NeuroAiD™ improved patients’ chances of performing daily activities after stroke.

EN      
Jan 2013 Media Coverage NurAiD™II is featured on France 24 with an interview with neurologist and prescriber Dr Charles Siow, CEO David Picard and lead investigator of the CHIMES trial Prof Christopher Chen about bringing Chinese medicine into the Western standards to fill the gap of improving recovery after stroke. EN      

2011

Jul 2011 Press Release Moleac Announces the Beneficial Effect of NeuroAiD (TM) (MLC 901) in Protecting the Brain Against Global Ischemia

“Neuropharmacology” published a paper establishing NeuroAiD’s reparativeeffects on global cerebral ischemia.

EN      
Feb 2011 Press Release Prof. Michel Lazdunski receives Gold Medal from the Jung Foundation for his work on ion channels.

We are happy to announce that Prof. Michel Lazdunski, vice president research of Moleac, has been awarded one of the most prestigious international awards – the 2011 Gold Medal of the Jung Foundation for Science and Research, for his work on ion channels.

EN      

2010

Mar 2010 Press Release Moleac Receives BioSpectrum Asia Emerging Company of the Year 2010 Award

Moleac Pte Ltd has been granted the Emerging Company of the Year 2010 Award, by Biospectrum, the leading integrated media platform for the Life Science Industry in Asia Pacific.

EN      
Feb 2010 Press Release Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD

The January issue of “Neuropharmacology”, publishes the article entitled “Neuroprotective and Neuroproliferative Activities of NeuroAiD”, reporting pharmacological data establishing NeuroAiD (MLC 601) protective effects on neuronal and brain injuries as well as its effectiveness in neurological functions recovery.

EN      

2009

Sep 2009 The Business Times Faster, cheaper way to developing drugs (next paragraph) Moleac’s hybrid approach has been used to successfully develop and market its stroke recovery drug in 3 years, for less than US$10m EN      
Apr 2009 Press Release Moleac named Singapore Entrepreneurial Company of the year at the Frost & Sullivan Excellence in Healthcare Award

An important confirmation of Moleacs outstanding performance in 2008.

EN      
Apr 2009 The Business Time Moleac is rewarded for its stroke treatment drug NeuroAiD EN      
Apr 2009 Medical Tribune TCM agent shows promise in post-stroke recovery, says study
An article on clinical trials performed in China shows promising results and paves the first steps towards making NeuroAiD an evidence-based medicine.
EN      
Feb 2009 Press Release Moleac Prof. Michel Lazdunski appointed as Vice-President Research of Moleac Pte. Ltd.

A world-renown scientific leader is now in charge of the study on NeuroAiD mechanism of action.

EN      
Feb 2009 Medical Tribune Evidence-based TCM makes headway
NeuroAiD™ is one of the first TCM medications to be put under the microscope of rigidly-controlled clinical trials CHIMES continues to make noises in Singapore and giving hope to stroke patients.
EN      

2008

Dec 2008 BioSpectrum Ancient medicines, source of Pharma innovation – Moleac aims to bring the science behind traditional medicines to the next level and establishes their quality and safety through accepted modern evaluation practices. EN      
Oct 2008 Le Quotidien du Medecin (original in French) Un composé issu de la médecine chinoise au banc d’essai. L’un des magazines les plus renommés parmi les médecins français a accordé une attention particulière à NeuroAiD™.

A mixture derived from Chinese medicine on trial. One of the most prestigious magazine for doctors in France has paid special attention to NeuroAid&trade.

FR      
May 2008 The Edge Bridging the gap between East and West – Moleac unique business model differs itself from other biotech companies in valuations or the way in which the investors consider. EN      
Apr 2008 The Business
Times Weekend News
China Stroke Drug Holds Promise. EN      
Apr 2008 The Business
Times Weekend News
Three-Minute Digest: US$3.5M
more for Moleac for stroke drug
trials.
EN      

2007

Sep 2007 The Business
Times Weekend
Largest TCM trial outside China. EN      
Sep 2007 Singapore Straits Times TCM drug for stroke to undergo clinical trials. EN      
Sep 2007 Channel News Asia Channel News Asia 880 stroke patients in Singapore to undergo TCM clinical trial. EN wmv
Sep 2007 The Business Times The Business Times Moleac plans to test traditional Chinese stroke drug. EN      
Sep 2007 Moleac announces CHIMES Largest ever clinical trial on stroke recovery medication to be initiated in Singapore and Philippines. EN      
Sep 2007 Reuters Singapore firm tests traditional Chinese stroke drug. EN      
May 2007 Medical News Today Going West with Eastern Medicine. EN      
Apr 2007 AsiaOne Chinese medicine to help stroke victims EN      
Apr 2007 Straits Times Rise of Traditional Chinese Medicine EN      

2006

Dec 2006 Reuters Moleac Turns TCM into Stroke Treatment EN      
Dec 2006 Focus Autumn Moleac: Therapeutics from East to West. EN      
Dec 2006 Today’s Manager Uncovering New Drugs from Traditional Cures. EN      
Oct 2006 The Business Times New TCM drug offers hope for stroke patients. EN      
Sep 2006 Press release Moleac and China healthcare tie up to offer a more comprehensive rehabilitation treatment for stroke patients. EN      
Aug 2006 The Edge Traditional Therapy EN      
Aug 2006 Talking Science (children magazine) East meets West EN      
Aug 2006 EZHealth NeuroAiD for stroke patients EN      
Jun 2006 Press release NeuroAiD offers new hope to patients EN      
Apr 2006 Singapore Business Visitor The Next Wave EN      
Jan 2006 Asia Pacific Biotech Journal Moleac: Flowing Therapeutics from the East to the West and Expertise from the West to the East. EN      

Chinese Herbal Medicine May Have Delayed Benefit in Stroke

By | News

VIENNA, Austria — Long-term follow-up of a trial investigating a Chinese herbal supplement in patients with stroke suggests there may be some benefit after 6 to 18 months.

The Chinese Medicine NeuroAiD Efficacy on Stroke Recovery (CHIMES) study was an international randomized double-blind placebocontrolled trial of 3 months of treatment with the herbal supplement NeuroAiD (Moleac) started within 72 hours of symptom onset in 1100 patients with ischemic stroke.

The primary results, which were reported in 2013, showed a trend toward better functional outcomes in the treated group at 3 months, but this did not reach statistical significance.

Longer-term follow-up in the CHIMES-E (Extension) study, which reported outcomes up to 2 years in 880 patients, was reported by Narayanaswamy Venketasubramanian, MD, from the Raffles Neuroscience Centre, Singapore, here at the 24th European Stroke Conference (ESC).

“While the benefits of a 3-month treatment with NeuroAiD did not reach statistical significance for the primary endpoint at 2 years, the odds of functional independence defined as [modified Rankin Scale score] ≤ 1 was significantly increased at 6 months and persisted up to 18 months after a stroke,” he concluded.

The results were also published online April 22 in Cerebrovascular Diseases.

The CHIMES-E study population had an overall mean age of 61.8 years, with 318 (36%) women, and a mean baseline National Institutes of Health Stroke Scale score of 8.6. The treatment and placebo groups were balanced in baseline characteristics at the time of inclusion in CHIMES, and they were similar in terms of subsequent rehabilitation and intake of any Chinese herbal medicines during the study, the researchers state.

The primary endpoint of the extended follow-up study was the shift analysis on the modified Rankin Scale at 2 years. This was not significant but showed a trend toward benefit with NeuroAiD (odds ratio, 1.08; 95% confidence interval, 0.85 – 1.37; P = .543).

However, when analyzed according to patients showing a good functional outcome (modified Rankin Scale, 0 – 1), treatment was associated with significant benefit at the 6-, 12-, and 18-month points.

table

Dr Venketasubramanian noted that the Barthel index showed similar trends toward improvements in the treated group in the longterm follow-up. “So our results are consistent on more than one score.”

“It appears that a 3-month course of treatment may not show benefits immediately,” he commented to Medscape Medical News. “Our results suggest that we may have to wait a while to see the effects, and maybe treatment should be maintained longer term, to maximize effects.”

He added: “When the brain is injured it takes time to calm down, so differences in healing may take time to show up. The herbal extracts have shown neuroprotection and neuro-restoration properties in animal models. As the results appear to be delayed, this may suggest more restoration is taking place.”

The researchers are now in discussions about conducting a second trial with a longer period of therapy and a longer follow-up.

NeuroAiD is a combination of nine Chinese herbal extracts and nine animal components. A new formulation has recently been developed without the animal components, Dr Venketasubramanian said.

“We are hoping that the new formulation, which is manufactured in accordance with good clinical practice, will mean fewer tablets and a less expensive production process. It will also have the advantage of not needing the regulation necessary for animal products.”

Marketing information produced by Moleac claims that the herbal extracts contained in NeuroAiD have been shown to “stimulate brain self repair processes for stroke recovery.” This includes “increasing the number of mature neuronal cells” in mice models and “increasing neurite outgrowth and synaptogenesis” in neuronal cell cultures. It adds that the product reduced infarct volume in a rodent stroke model, increased cell survival, and “activates ATP-dependent K+ channels contributing to neuroprotection and ischemic preconditioning.”

The product is sold as an herbal supplement and is not regulated as a medicine at present.

The CHIMES-E study was supported by the CHIMES Society, a nonprofit organization, and grants were received by CLHC from the National Medical Research Council of Singapore. The authors received funding for the trial and accommodation and transportation support for meetings from the CHIMES Society. Moleac (Singapore) provided grants to the CHIMES Society, of which the society had sole discretion on use. One coauthor has minor shares in E*Chimes, the Philippine distributor of NeuroAiD. Other than CHIMES funding for the trial, the other authors and investigators have disclosed no relevant financial relationships.

Cerebrovasc Dis. 2015;39:309-318. Full text

24th European Stroke Conference (ESC). Presented May 14, 2015.